Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...
September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...
4don MSN
We recently compiled a list of the 8 Dividend Giants with Lowest Short Interest in 2024. In this article, we are going to ...
Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could offer insights into the health of the U.S.
3d
Wells Fargo analyst Mohit Bansal has maintained their neutral stance on BMY stock, giving a Hold rating on September 23. Mohit Bansal has ...
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show ...
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback